HMGA1/E2F1 axis and NFkB pathways regulate LPS progression and trabectedin resistance

Rossella Loria, Valentina Laquintana, Giulia Bon, Daniela Trisciuoglio, Roberta Frapolli, Renato Covello, Carla Azzurra Amoreo, Virginia Ferraresi, Carmine Zoccali, Mariangela Novello, Donatella Del Bufalo, Michele Milella, Roberto Biagini, Maurizio D’Incalci, Rita Falcioni

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Although the medical treatments of sarcoma have evolved in the last years, a significant portion of patients develops recurrence after therapies suggesting the need to identify novel targets to improve the treatments. By the use of patient-derived and established cell lines from liposarcoma, as well as specimens from patient biopsies, we found that HMGA1 is involved in the progression of dedifferentiated and myxoid liposarcoma. The immunohistochemical and RT-PCR analyses of 68 liposarcoma specimens revealed a significant high expression of HMGA1, at the protein and RNA levels, both in myxoid and dedifferentiated liposarcoma subtypes compared with differentiated ones. Loss- and gain-of-function experiments by HMGA1-specific depletion and overexpression in dedifferentiated and myxoid liposarcoma cells showed the contribution of this oncogenic factor in cell proliferation, motility, invasion, and drug resistance. The in vitro and in vivo treatment of myxoid liposarcoma with trabectedin, a drug with a potent anti-tumor activity, revealed downregulation of HMGA1, E2F1, and its-downstream targets, vimentin and ZEB1, indicating a critical role of trabectedin in inhibiting the mesenchymal markers of these tumors through the HMGA1/E2F1 axis. These data were also confirmed in patients’ tumor biopsies being HMGA1, E2F1, and vimentin expression significantly reduced upon trabectedin therapy, administered as neo-adjuvant chemotherapy. Furthermore, trabectedin treatment inhibits in vitro NFkB pathway in mixoyd liposarcoma sensitive but not in resistant counterparts, and the inhibition of NFkB pathway re-sensitizes the resistant cells to trabectedin treatment. These data support the rational for combining NFkB inhibitors with trabectedin in liposarcoma patients, who have become resistant to the drug.

Original languageEnglish
Pages (from-to)5926-5938
Number of pages13
JournalOncogene
Volume37
Issue number45
DOIs
Publication statusPublished - Nov 8 2018

Fingerprint

trabectedin
Liposarcoma
Myxoid Liposarcoma
Vimentin
Therapeutics
Biopsy
Adjuvant Chemotherapy
Tumor Biomarkers
Drug Resistance
Sarcoma
Pharmaceutical Preparations
Cell Movement

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

HMGA1/E2F1 axis and NFkB pathways regulate LPS progression and trabectedin resistance. / Loria, Rossella; Laquintana, Valentina; Bon, Giulia; Trisciuoglio, Daniela; Frapolli, Roberta; Covello, Renato; Amoreo, Carla Azzurra; Ferraresi, Virginia; Zoccali, Carmine; Novello, Mariangela; Del Bufalo, Donatella; Milella, Michele; Biagini, Roberto; D’Incalci, Maurizio; Falcioni, Rita.

In: Oncogene, Vol. 37, No. 45, 08.11.2018, p. 5926-5938.

Research output: Contribution to journalArticle

@article{0969c06e0d6048f5abf850e05d96e402,
title = "HMGA1/E2F1 axis and NFkB pathways regulate LPS progression and trabectedin resistance",
abstract = "Although the medical treatments of sarcoma have evolved in the last years, a significant portion of patients develops recurrence after therapies suggesting the need to identify novel targets to improve the treatments. By the use of patient-derived and established cell lines from liposarcoma, as well as specimens from patient biopsies, we found that HMGA1 is involved in the progression of dedifferentiated and myxoid liposarcoma. The immunohistochemical and RT-PCR analyses of 68 liposarcoma specimens revealed a significant high expression of HMGA1, at the protein and RNA levels, both in myxoid and dedifferentiated liposarcoma subtypes compared with differentiated ones. Loss- and gain-of-function experiments by HMGA1-specific depletion and overexpression in dedifferentiated and myxoid liposarcoma cells showed the contribution of this oncogenic factor in cell proliferation, motility, invasion, and drug resistance. The in vitro and in vivo treatment of myxoid liposarcoma with trabectedin, a drug with a potent anti-tumor activity, revealed downregulation of HMGA1, E2F1, and its-downstream targets, vimentin and ZEB1, indicating a critical role of trabectedin in inhibiting the mesenchymal markers of these tumors through the HMGA1/E2F1 axis. These data were also confirmed in patients’ tumor biopsies being HMGA1, E2F1, and vimentin expression significantly reduced upon trabectedin therapy, administered as neo-adjuvant chemotherapy. Furthermore, trabectedin treatment inhibits in vitro NFkB pathway in mixoyd liposarcoma sensitive but not in resistant counterparts, and the inhibition of NFkB pathway re-sensitizes the resistant cells to trabectedin treatment. These data support the rational for combining NFkB inhibitors with trabectedin in liposarcoma patients, who have become resistant to the drug.",
author = "Rossella Loria and Valentina Laquintana and Giulia Bon and Daniela Trisciuoglio and Roberta Frapolli and Renato Covello and Amoreo, {Carla Azzurra} and Virginia Ferraresi and Carmine Zoccali and Mariangela Novello and {Del Bufalo}, Donatella and Michele Milella and Roberto Biagini and Maurizio D’Incalci and Rita Falcioni",
year = "2018",
month = "11",
day = "8",
doi = "10.1038/s41388-018-0394-x",
language = "English",
volume = "37",
pages = "5926--5938",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "45",

}

TY - JOUR

T1 - HMGA1/E2F1 axis and NFkB pathways regulate LPS progression and trabectedin resistance

AU - Loria, Rossella

AU - Laquintana, Valentina

AU - Bon, Giulia

AU - Trisciuoglio, Daniela

AU - Frapolli, Roberta

AU - Covello, Renato

AU - Amoreo, Carla Azzurra

AU - Ferraresi, Virginia

AU - Zoccali, Carmine

AU - Novello, Mariangela

AU - Del Bufalo, Donatella

AU - Milella, Michele

AU - Biagini, Roberto

AU - D’Incalci, Maurizio

AU - Falcioni, Rita

PY - 2018/11/8

Y1 - 2018/11/8

N2 - Although the medical treatments of sarcoma have evolved in the last years, a significant portion of patients develops recurrence after therapies suggesting the need to identify novel targets to improve the treatments. By the use of patient-derived and established cell lines from liposarcoma, as well as specimens from patient biopsies, we found that HMGA1 is involved in the progression of dedifferentiated and myxoid liposarcoma. The immunohistochemical and RT-PCR analyses of 68 liposarcoma specimens revealed a significant high expression of HMGA1, at the protein and RNA levels, both in myxoid and dedifferentiated liposarcoma subtypes compared with differentiated ones. Loss- and gain-of-function experiments by HMGA1-specific depletion and overexpression in dedifferentiated and myxoid liposarcoma cells showed the contribution of this oncogenic factor in cell proliferation, motility, invasion, and drug resistance. The in vitro and in vivo treatment of myxoid liposarcoma with trabectedin, a drug with a potent anti-tumor activity, revealed downregulation of HMGA1, E2F1, and its-downstream targets, vimentin and ZEB1, indicating a critical role of trabectedin in inhibiting the mesenchymal markers of these tumors through the HMGA1/E2F1 axis. These data were also confirmed in patients’ tumor biopsies being HMGA1, E2F1, and vimentin expression significantly reduced upon trabectedin therapy, administered as neo-adjuvant chemotherapy. Furthermore, trabectedin treatment inhibits in vitro NFkB pathway in mixoyd liposarcoma sensitive but not in resistant counterparts, and the inhibition of NFkB pathway re-sensitizes the resistant cells to trabectedin treatment. These data support the rational for combining NFkB inhibitors with trabectedin in liposarcoma patients, who have become resistant to the drug.

AB - Although the medical treatments of sarcoma have evolved in the last years, a significant portion of patients develops recurrence after therapies suggesting the need to identify novel targets to improve the treatments. By the use of patient-derived and established cell lines from liposarcoma, as well as specimens from patient biopsies, we found that HMGA1 is involved in the progression of dedifferentiated and myxoid liposarcoma. The immunohistochemical and RT-PCR analyses of 68 liposarcoma specimens revealed a significant high expression of HMGA1, at the protein and RNA levels, both in myxoid and dedifferentiated liposarcoma subtypes compared with differentiated ones. Loss- and gain-of-function experiments by HMGA1-specific depletion and overexpression in dedifferentiated and myxoid liposarcoma cells showed the contribution of this oncogenic factor in cell proliferation, motility, invasion, and drug resistance. The in vitro and in vivo treatment of myxoid liposarcoma with trabectedin, a drug with a potent anti-tumor activity, revealed downregulation of HMGA1, E2F1, and its-downstream targets, vimentin and ZEB1, indicating a critical role of trabectedin in inhibiting the mesenchymal markers of these tumors through the HMGA1/E2F1 axis. These data were also confirmed in patients’ tumor biopsies being HMGA1, E2F1, and vimentin expression significantly reduced upon trabectedin therapy, administered as neo-adjuvant chemotherapy. Furthermore, trabectedin treatment inhibits in vitro NFkB pathway in mixoyd liposarcoma sensitive but not in resistant counterparts, and the inhibition of NFkB pathway re-sensitizes the resistant cells to trabectedin treatment. These data support the rational for combining NFkB inhibitors with trabectedin in liposarcoma patients, who have become resistant to the drug.

UR - http://www.scopus.com/inward/record.url?scp=85049600092&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049600092&partnerID=8YFLogxK

U2 - 10.1038/s41388-018-0394-x

DO - 10.1038/s41388-018-0394-x

M3 - Article

C2 - 29980789

AN - SCOPUS:85049600092

VL - 37

SP - 5926

EP - 5938

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 45

ER -